Farringdon Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Farringdon Capital’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-697	Closed	-$215K	–	502
2024 Q4	$215K	Buy	+697	New	+$196K	0.09%	368

Other funds holding MDGL

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Farringdon Capital's MDGL Position: Q1 2025 in Review

Farringdon Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2025, closing a stake of 697 shares — an estimated $215K sold.

Farringdon Capital first reported a position in MDGL in Q4 2024 and held it in 1 quarter. The position peaked at $215K in Q4 2024. 321 funds tracked by Wall St. Rank hold MDGL as of Q1 2025.

Farringdon Capital reported no remaining Madrigal Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Farringdon Capital sold 697 Madrigal Pharmaceuticals shares in Q1 2025, an estimated $215K.
Farringdon Capital first reported a position in Madrigal Pharmaceuticals in Q4 2024 and held it in 1 quarter.
Farringdon Capital's Madrigal Pharmaceuticals position peaked at $215K in Q4 2024.
321 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2025.

Based on Farringdon Capital's 13F filing for Q1 2025, filed 15 May 2025.